Clinical Trials Logo

Porphyrias clinical trials

View clinical trials related to Porphyrias.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05882136 Completed - Porphyrias, Hepatic Clinical Trials

Acute Intermittent Porphyria Related Abnormalities in Cardiovascular System

AIPRACUS
Start date: April 5, 2019
Phase:
Study type: Observational

This study aims to assess the changes in the cardiovascular system in patients with acute intermittent porphyria (AIP).

NCT ID: NCT05854784 Completed - Variegate Porphyria Clinical Trials

Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

Start date: March 28, 2023
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the impact of afamelanotide on the severity of skin disease in patients with Variegate Porphyria (VP). The secondary objectives are to evaluate the safety and tolerability of afamelanotide in patients with VP and evaluate the impact of afamelanotide on the quality of life of patients with VP.

NCT ID: NCT03906214 Completed - Porphyrias Clinical Trials

Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

Start date: April 3, 2019
Phase:
Study type: Observational

This is an observational study collecting patient/caregiver reports on suspected medication/drug-induced acute porphyria attacks, as well as safe use of drugs previously labeled "unsafe" or with unknown risk. Participants will be recruited through the RDCRN Contact Registry for the Porphyrias Consortium. The study will be advertised on the Consortium website and through the American Porphyria Foundation's social media network.

NCT ID: NCT03505853 Completed - Clinical trials for Acute Intermittent Porphyria (AIP)

A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

Start date: April 26, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of givosiran on the pharmacokinetics of the 5-probe cocktail of midazolam, caffeine, losartan, omeprazole, and dextromethorphan, and their metabolites, in asymptomatic patients with Acute Intermittent Porphyria.

NCT ID: NCT03338816 Completed - Clinical trials for Acute Intermittent Porphyria

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Start date: November 16, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).

NCT ID: NCT03118674 Completed - Hepatitis C Clinical Trials

Harvoni Treatment Porphyria Cutanea Tarda

Start date: September 6, 2017
Phase: Phase 2
Study type: Interventional

In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.

NCT ID: NCT02949830 Completed - Clinical trials for Acute Intermittent Porphyria

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).

NCT ID: NCT02943213 Completed - Clinical trials for Acute Intermittent Porphyria

Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride

Start date: November 2016
Phase: Phase 1
Study type: Interventional

Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD. The aim of this pilot study is to investigate intrasubject variability in the bioavailability of Chlorpromazine Hydrochloride 25 mg sugar coated tablets. Cycle aims to demonstrate that Chlorpromazine Hydrochloride has a shallow dose response curve and a wide safety margin. This will then allow for the modification of bioequivalence acceptance criteria in future pivotal studies which will reduce the number of participants required whilst still maintaining assurance of safety and efficacy. Pilot Subjects (n): 20 Periods: 2 (2xR) Dosing: Single-dose Strength: 25 mg Test Product: N/A Reference: USL PHARMA Chlorpromazine Hydrochloride Analytes (in plasma): Chlorpromazine; 7-Hydroxychlorpromazine Bioequivalence based on 90% CI (Cmax, AUC): Standard; 80.00 - 125.00%

NCT ID: NCT02452372 Completed - Clinical trials for Acute Intermittent Porphyria

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Start date: May 6, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1) in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.

NCT ID: NCT02240784 Completed - Clinical trials for Acute Hepatic Porphyria

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Start date: August 2014
Phase:
Study type: Observational

The purpose of this study is to characterize the natural history and clinical management of Acute Hepatic Porphyria (AHP) patients with recurring attacks.